Pathologic and prognostic impacts of <i>FGFR2</i> amplification in gastric cancer: a meta-analysis and systemic review

Kim, Hyeong Su; Kim, Jung Han; Jang, Hyun Joo

doi:10.7150/jca.29184



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(11):2560-2567. doi:10.7150/jca.29184 This issue Cite

Research Paper

Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review

Hyeong Su Kim¹, Jung Han Kim^1✉, Hyun Joo Jang^2✉

1. Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea
2. Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Hwasung, Republic of Korea

Citation:

Kim HS, Kim JH, Jang HJ. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J Cancer 2019; 10(11):2560-2567. doi:10.7150/jca.29184. https://www.jcancer.org/v10p2560.htm

Other styles

Abstract

Fibroblast growth factor receptor-2 (FGFR2) gene is amplified in up to 15% of patients with gastric cancer (GC). However, the prognostic significance of FGFR2 amplification has been controversial. This meta-analysis was conducted to evaluate the clinicopathological impacts of FGFR2 amplification in patients with GC. We performed a systematic computerized search of the electronic databases of PubMed, PMC, EMBASE, Web of Science, and Google Scholar and selected studies assessing the correlation of FGFR2 amplification with pathologic features and/or prognosis in gastric adenocarcinoma. From eight studies, 2,377 patients were included in the pooled analysis of odds ratios (ORs) with 95% confidence intervals (CIs) for pathologic findings and hazard ratios (HRs) with 95% CIs for overall survival. FGFR2 amplification was significantly associated with LN metastasis (OR = 3.93, 95% CI: 2.22-6.96, p < 0.00001) and poorly differentiated adenocarcinoma (OR = 2.36, 95% CI: 1.03-5.39, p = 0.04). In addition, patients with GC harboring FGFR2 amplification showed significantly worse survival (HR = 2.09, 95% CI: 1.68-2.59, p < 0.00001), compared with patients with FGFR2-unamplified GC. In conclusion, this meta-analysis indicates that FGFR2 amplification is an adverse prognostic factor in patients with GC.

Keywords: FGFR2 amplification, gastric cancer, prognosis, meta-analysis, review

Citation styles

APA

Kim, H.S., Kim, J.H., Jang, H.J. (2019). Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. Journal of Cancer, 10(11), 2560-2567. https://doi.org/10.7150/jca.29184.

ACS

Kim, H.S.; Kim, J.H.; Jang, H.J. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J. Cancer 2019, 10 (11), 2560-2567. DOI: 10.7150/jca.29184.

NLM

CSE

Kim HS, Kim JH, Jang HJ. 2019. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J Cancer. 10(11):2560-2567.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.